Novartis will make waves in gene therapy, says head of biomedical research
This article was originally published in Scrip
Executive Summary
Novartis, unlike several of its big pharma peers, has itself a healthy looking pipeline now and for the foreseeable future – allowing the company the luxury of "being a bit choosy" when it comes to selecting investments.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.